iRhythm Holdings, Inc. (IRTC) Stock Price & How to Invest
Last updated November 2026
Short answer
IRTC is iRhythm Holdings (formerly iRhythm Technologies), the company behind the Zio patch, the most widely prescribed long-term ambulatory ECG monitor in the US. It is a fast-growing (about 15% revenue growth in the latest quarter), gross-margin-rich medtech that is adjusted-EBITDA positive but still loss-making on a GAAP basis. As of November 20, 2026 the stock sits near $95, down about 46% year to date, with a market cap of about $3.2 billion, after third-quarter results showed slower growth and a soft spot in one product line following its VitalConnect acquisition. In November the board approved a $200 million buyback and launched a $100 million accelerated repurchase.
IRTC stock price
As of 2026-11-20, iRhythm Holdings, Inc. (IRTC) last closed at $94.72, down 46.7% over the past year. Over the past 52 weeks it has traded between $86.06 and $189.25.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or iRhythm Holdings, Inc.'s investor relations page. Walnut is informational, not investment advice.
IRTC key stats
At $94.72 on November 20, 2026, iRhythm Holdings, Inc. (IRTC) has a market cap of $3.2B.
- Market cap
- $3.2B
- P/E (forward)
- 61.6
- Price to book
- 17.9
- Beta
- 1.47
Market cap, P/E and yield are measured at the $94.72 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with iRhythm Holdings, Inc. (IRTC)?
The last two weeks for iRhythm Holdings, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- IRTC closed at $94.72 on November 20, 2026, up 3.1% over the past five trading days (from $91.91).
- On November 17, 2026, iRhythm Holdings, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) and other events (Item 7.01, Item 8.01). Read the 8-K on sec.gov
- On November 13, 2026, iRhythm Holdings, Inc. filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
- On November 12, 2026, iRhythm Holdings, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) and other events (Item 7.01, Item 8.01). Read the 8-K on sec.gov
- On November 11, 2026, Stephens & Co. lowered its target to $120.00 from $160.00 (Overweight).
- On November 9, 2026, Truist Securities lowered its target to $140.00 from $168.00 (Buy).
- On November 9, 2026, Freedom Capital Markets lowered its target to $159.00 from $190.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
iRhythm Holdings, Inc. (IRTC) latest quarter
iRhythm reported revenue of $222 million for Q3 2026, up 15% from a year earlier (iRhythm, Nov 5, 2026).
Source: iRhythm Q3 2026 results, Nov 5, 2026. Full earnings breakdown
What does iRhythm Holdings, Inc. (IRTC) do?
iRhythm makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. The device replaced the older Holter-monitor workflow (short-window, wired recorders) with a longer, more comfortable, water-resistant patch that is mailed back for algorithmic analysis and a physician report. Zio has become the most widely prescribed ambulatory ECG monitor in the US, and iRhythm is extending the franchise with mobile cardiac telemetry, international expansion, and adjacencies such as sleep apnea and primary-care risk stratification. In October 2026 it completed the acquisition of VitalConnect, a wearable-biosensor company with a 30-day mobile cardiac telemetry platform that can track up to 11 physiological parameters, for $237.5 million in cash plus up to about 423,000 shares.
The investment picture is a classic high-growth medtech profile. Trailing revenue is about $854 million, up from $747 million in fiscal 2025, gross margin sits near 72%, and Q3 2026 revenue of about $221.6 million rose about 14.9% year over year, slightly below the roughly $222.3 million consensus and down from about 20% growth in Q2. Adjusted EBITDA reached a record of about $51 million (a 23% margin), and adjusted EPS of $0.82 was far above the $0.05 estimate, but the GAAP loss widened to about $30 million in the quarter and about $39 million over the trailing twelve months, while free cash flow was about $82 million. Management nudged its 2026 revenue guidance midpoint up to about $892.5 million, about 1.5% below what analysts had expected, and said Zio AT revenue was flat as customers delayed purchases until the VitalConnect integration settles, a drag it expects for a quarter or two. The shares fell about 12% on the report and kept sliding: at about $95 on November 20, 2026 the stock was down roughly 46% year to date and 44% over one year, near the bottom of its $83-$192 52-week range. The board then approved a $200 million share repurchase program and signed a $100 million accelerated repurchase, and an insider bought about $764,000 of stock. At about 3.7 times sales and 62 times forward earnings, the valuation still embeds continued volume growth, margin expansion and successful product launches, which keeps IRTC sensitive to reimbursement changes, FDA outcomes and any further slowdown in prescriptions.
What's driving iRhythm Holdings, Inc. (IRTC)?
1. Zio volume growth and category leadership
The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. Revenue was about $199 million in Q1 2026, $224 million in Q2 and $222 million in Q3, with Q3 up about 15% year over year, and trailing revenue is now about $854 million. Management expects mid-teens growth in the Zio monitor business, helped by primary care and newer channels. As the most widely prescribed ambulatory ECG monitor in the US, iRhythm benefits from installed physician habit and a large recurring stream of new patient prescriptions. Analysts expect about $248 million of revenue for Q4 2026 and about $893 million for the full year, in line with guidance near $892.5 million.
2. Mobile cardiac telemetry: Zio MCT plus VitalConnect
iRhythm has submitted its next-generation Zio MCT (mobile cardiac telemetry) platform to the FDA and has targeted a first-half 2027 launch for the AI-enabled version. In October 2026 it added VitalConnect, whose FDA-cleared MCT platform supports up to 30-day monitoring, live look-in and up to 11 physiological parameters, extending iRhythm into inpatient and hospital-to-home care. Management expects the deal to lift its revenue growth rate starting in 2027 and has kept its previously stated 15% adjusted-EBITDA margin target for 2027. The near-term cost showed up in Q3: Zio AT revenue was flat as customers waited for the integration, which management said may take a quarter or two to clear.
3. Margin expansion toward profitability
Gross margin sits near 72%, adjusted EBITDA hit a record of about $51 million in Q3 2026 (a 23% margin, against about $28 million expected), and free cash flow over the last twelve months was about $82 million. GAAP results moved the other way, with a Q3 net loss of about $30 million against a near break-even Q2, and the trailing operating margin slipped to about 4.5%. Operating leverage on a largely fixed analysis and sales infrastructure means incremental volume can flow through at high margins, and analyst estimates call for EPS of about $1.29 in 2026 and $1.54 in 2027 on an adjusted basis. The narrative has moved from pure top-line growth toward a path to sustained profitability, with a buyback now part of capital allocation.
4. New markets and payer coverage
Growth catalysts include international expansion, deeper penetration in primary care and population health through risk-stratification partnerships, and adjacencies such as obstructive sleep apnea. US payer coverage reaches about 93% of lives, reducing reimbursement friction for prescribers. These channels give iRhythm several independent levers to extend growth beyond its core cardiology base.
What are the risks to iRhythm Holdings, Inc. (IRTC)?
Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. Growth is slowing (about 15% in Q3 2026 after about 20% in Q2), and management warned that VitalConnect integration may keep Zio AT sales soft for a quarter or two; Citi downgraded the stock after the report. Data security became a live issue in 2026: unauthorized individuals accessed and downloaded patient information (names, contact details, insurance numbers, dates of birth) from third-party-hosted business applications between June 3 and June 8, 2026, and iRhythm began notifying affected patients on October 2. The company says it does not expect a material financial impact and saw no effect on its devices or patient safety, but breaches can bring litigation and regulatory scrutiny. The balance sheet carries about $726 million of debt against about $561 million of cash at September 30, 2026, and the $100 million accelerated buyback will draw that cash down further. The company is still loss-making on a GAAP basis and trades at a premium earnings multiple, so any volume slowdown, pricing pressure or launch delay could compress the stock further, as its 46% drop in 2026 shows. Competition from larger, better-capitalized players (Philips, Boston Scientific) adds further risk, and medtech reimbursement and regulatory outcomes are difficult to predict.
What is the iRhythm Holdings, Inc. (IRTC) forecast?
15 analysts publish price targets on IRTC, averaging $153.27 as of November 2026, or +61.8% against the $94.72 share price on November 20, 2026. The published targets run from $120.00 to $206.00, a moderate spread, and the ratings split 15 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 10 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full IRTC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is IRTC a buy or a sell?
We give no verdict on iRhythm Holdings, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Zio volume growth and category leadership. The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. The most optimistic published target, $206.00, assumes this works close to its best case.
The case against. Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. The most pessimistic target, $120.00, is roughly what IRTC is worth if this bites instead.
Read the full bull and bear case on IRTC, including what would have to change to break either one. Walnut is not an investment adviser.
Has iRhythm Holdings, Inc. (IRTC) split its stock?
No. iRhythm Holdings, Inc. (IRTC) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is iRhythm Holdings, Inc. (IRTC) valued?
Market cap, P/E and dividend yield at today's price are in the IRTC key stats above. The business figures below come from iRhythm Holdings, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$854M; 2026 guidance midpoint ~$892.5M
- Q3 2026 revenue growth: ~15% YoY (~$221.6M, slightly below consensus)
- Gross / operating margin (TTM): ~72% / ~4.5%
- Adjusted EBITDA (Q3 2026): ~$51M, ~23% margin (record)
- Net income (TTM): ~-$39M; Q3 2026 ~-$30M
- Cash / debt: ~$561M / ~$726M; $200M buyback authorized, $100M ASR
As of November 2026: At about $95 on November 20, 2026, IRTC trades at roughly 3.7 times trailing sales and 62 times forward earnings, a lower sales multiple than earlier in the year after a 46% drop in the share price even as revenue kept growing in the mid-teens. GAAP earnings are still negative (no trailing P/E), so the valuation leans on volume growth, margin expansion and the MCT strategy more than current profits. The mean analyst target among 15 tracked by Yahoo was about $153, well above the price, and the board's decision to buy back up to $200 million of stock signals how management views the drop.
Who competes with iRhythm Holdings, Inc. (IRTC)?
Large diversified medtech
Philips (which acquired BioTelemetry) and Boston Scientific (which acquired Preventice Solutions) offer competing ambulatory cardiac monitoring services with far larger balance sheets and wider hospital relationships. GE Healthcare and other cardiology equipment makers also compete across cardiac monitoring.
Legacy monitoring technology
Traditional Holter monitors and short-window event recorders remain the incumbent alternatives that Zio is displacing. Their share has fallen from roughly 80% to around 40% of the market, and that shift toward long-term continuous monitoring is a core part of iRhythm's growth thesis.
Focused monitoring and diagnostics players
Smaller and regional cardiac-monitoring service providers, plus emerging patch and wearable ECG entrants and AI-ECG software companies such as Tempus AI, compete on price, turnaround, and physician relationships in what remains a fragmented market. iRhythm absorbed one of these players, VitalConnect, in October 2026.
What stocks are similar to iRhythm Holdings, Inc. (IRTC)?
Other names that sit close to IRTC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in iRhythm Holdings, Inc. (IRTC)
There are three common ways to get IRTC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IRTC sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where IRTC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on iRhythm Holdings, Inc. (IRTC)
IRTC is a category-leading cardiac-monitoring growth story whose revenue keeps compounding and whose adjusted margins keep improving, yet the stock has fallen sharply in 2026, including about 22% in the month after its Q3 report. The reward depends on continued Zio volume gains, a smooth VitalConnect integration and the Zio MCT launch, set against slowing growth, real regulatory, reimbursement and data-security risk. Management is now using cash to buy back stock, with $100 million committed through an accelerated repurchase.
More on iRhythm Holdings, Inc. (IRTC)
Whether IRTC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IRTC a buy or a sell?, and where the stock could go from here in the IRTC stock forecast.
For income investors, whether IRTC pays a dividend and how the payout looks is covered in does IRTC pay a dividend? And to weigh IRTC against a peer, read the full side-by-side comparisons: IRTC vs BSX and IRTC vs GE.
Wondering how IRTC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about iRhythm Holdings, Inc.
Ask Walnut's AI anything about IRTC and see how it fits what you own.
FAQ
What does iRhythm Technologies (IRTC) do?
+
iRhythm, now named iRhythm Holdings, makes the Zio service, an adhesive patch that continuously records a patient's heart rhythm for up to 14 days. The patch is mailed back and analyzed with AI-assisted algorithms to detect arrhythmias like atrial fibrillation, then a report is sent to the prescribing physician. Since October 2026 it also owns VitalConnect, which adds a 30-day mobile cardiac telemetry platform.
Is IRTC profitable?
+
Not on a GAAP basis. Trailing twelve-month net income is about -$39 million, and Q3 2026 showed a GAAP loss of about $30 million after a near break-even Q2. On an adjusted basis it is clearly profitable: Q3 adjusted EBITDA was a record of about $51 million, a 23% margin, and the company produced about $82 million of free cash flow over the last twelve months.
How fast is iRhythm growing?
+
Trailing revenue is about $854 million, up from $747 million in fiscal 2025, and Q3 2026 revenue of about $221.6 million grew about 15% year over year, slower than the roughly 20% in Q2. Management guides to about $892.5 million for 2026, and analysts expect about $1.07 billion for 2027. Growth is driven by rising Zio prescription volumes and expanding payer coverage, and management expects VitalConnect to add to the growth rate from 2027.
What is the Zio MCT and why does it matter?
+
Zio MCT is iRhythm's next-generation mobile cardiac telemetry platform, submitted to the FDA with an AI-enabled version targeted for a first-half 2027 launch. It expands iRhythm into real-time, higher-acuity monitoring, a larger addressable market beyond the mail-back patch. The VitalConnect acquisition gives iRhythm a second, already FDA-cleared MCT platform with up to 30-day monitoring and multi-vital tracking.
Who competes with iRhythm?
+
Major competitors include Philips (which acquired BioTelemetry) and Boston Scientific (which acquired Preventice), along with GE Healthcare, AI-ECG software players such as Tempus AI, and numerous smaller monitoring providers. Legacy Holter monitors remain the incumbent technology that Zio is steadily displacing.
What are the biggest risks for IRTC?
+
The main risks are regulatory (FDA warning-letter remediation and clearance timing for new products) and reimbursement (dependence on CMS and commercial payer rates). Growth slowed to about 15% in Q3 2026, the VitalConnect integration has delayed some Zio AT purchases, a June 2026 data breach exposed patient contact and insurance details, and the company carries about $726 million of debt. Its premium valuation, GAAP losses and competition from larger firms add to the risk profile.
Why does IRTC trade at such a high valuation?
+
IRTC carries a market cap of about $3.2 billion on about $854 million of trailing revenue, roughly 3.7 times sales and 62 times forward earnings, a premium typical of high-growth medtech. The multiple has come down in 2026 as the share price fell about 46% while revenue kept growing. It still reflects expectations of continued volume growth, margin expansion and successful new-product launches more than current GAAP earnings.
How did iRhythm do in its latest quarter?
+
In Q3 2026 (quarter ended September 30), reported November 5, revenue was about $221.6 million, up about 14.9% year over year and slightly below consensus. Adjusted EPS of $0.82 was far above the roughly $0.05 estimate and adjusted EBITDA reached a record $51 million, but the GAAP net loss was about $30 million. Management raised its 2026 revenue guidance midpoint slightly to about $892.5 million and flagged flat Zio AT sales while VitalConnect is integrated; the stock fell about 12% on the report.
How has IRTC stock performed in 2026?
+
Poorly relative to the business. As of November 20, 2026 the stock closed near $95, down about 46% year to date and about 44% over one year, and about 22% over the past month after the Q3 report, close to the low end of its $83-$192 52-week range. Analysts' mean price target is about $153 across 15 analysts, though targets are opinions and not a forecast Walnut endorses.
Is iRhythm buying back stock?
+
Yes. On November 11, 2026 the board approved a $200 million share repurchase program, and on November 17 iRhythm signed a $100 million accelerated share repurchase agreement under it. An insider also disclosed buying about $764,000 of shares in November. The buyback uses part of the roughly $561 million of cash the company held at September 30, 2026.
How can someone invest in IRTC?
+
IRTC trades on the Nasdaq and can be bought through any standard brokerage account, as a single stock or as part of a thematic basket of healthcare or medtech names. Because it is a volatile growth stock that is not yet consistently profitable, many investors weigh position sizing and diversification carefully. Walnut is not an investment adviser and this is not a recommendation.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with iRhythm Holdings, Inc.'s investor relations page or your broker before making investment decisions.